Organization (Industry)
Biohaven Ltd.
ClinicalTrials.gov lists Biohaven Ltd. as lead sponsor of 41 trials, counting the companies grouped under it. Biohaven Ltd. itself has 12 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Pfizer, Team, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Biohaven Ltd. and 2 companies grouped under it: 41 lead-sponsored trials (15 its own, 26 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Biohaven Therapeutics Ltd. | 19 | 0 |
| Pyramid Biosciences | 7 | 0 |
Disease areas (23)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Anxiety Disorders | 6 |
| Obsessive-Compulsive Disorder | 4 |
| Cerebellar Ataxia | 3 |
| Amyotrophic Lateral Sclerosis | 3 |
| Ataxia | 3 |
Showing 5 of 23 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 3 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 1 |
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Troriluzole | Spinocerebellar Ataxias | Phase 3 | 3 |
| Troriluzole | Cerebellar Ataxia | Phase 3 | 3 |
| Troriluzole | Ataxia | Phase 3 | 3 |
| Troriluzole | Machado-Joseph Disease | Phase 3 | 1 |
| Troriluzole | Heart Arrest | Phase 3 | 1 |
Showing 5 of 12 active programs.
Approved assets (1)
| Drug | Trials |
|---|---|
| Riluzole | 2 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=12) | 9% on time (n=11) |
SEC-reported annual financials (7)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | not reported | -738,822,000 | 635,065,000 |
| 2024 | not reported | -846,422,000 | 795,871,000 |
| 2023 | not reported | -408,168,000 | 373,281,000 |
| 2022 | not reported | -570,279,000 | 437,072,000 |
| 2021 | not reported | -213,796,000 | 181,486,000 |
| 2020 | not reported | -118,668,000 | 98,460,000 |
| 2019 | not reported | not reported | not reported |
FDA untitled letters (1)
| Issue date | Letter |
|---|---|
| 2021-03-08 | 146528 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Biohaven Pharmaceuticals, Inc | New Haven, US | FDA |
Biomarker capability evidence (85)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACHE | Trial sponsor | Named in trial inclusion criteria |
| ATXN1 | Trial sponsor | Named in trial inclusion criteria |
| ATXN1 | Trial sponsor | Named in trial inclusion criteria |
| ATXN10 | Trial sponsor | Named in trial inclusion criteria |
| ATXN10 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 85 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: financing and grant events, fda warning letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under Pfizer Inc: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.